Condition: Neoplastic Disease · Glioblastoma · Glioblastoma (GBM) · Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.
This description comes directly from the study's public registry record.
Clinical Project Manager · 2154902000 · samuel.park@telixpharma.com
Back-up Clinical Project Manager · neil.smith@telixpharma.com
Always discuss trial participation with your own doctor first.
| Gold Coast University Hospital | Gold Coast, Queensland, Australia | Recruiting |
| Austin Health | Melbourne, Australia | Recruiting |
| Johannes Kepler University | Linz, Austria | Recruiting |
| UMC Utrecht | Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07100730